Ontology highlight
ABSTRACT:
SUBMITTER: Apperley JF
PROVIDER: S-EPMC4979080 | biostudies-literature | 2009 Jul
REPOSITORIES: biostudies-literature
Apperley Jane F JF Cortes Jorge E JE Kim Dong-Wook DW Roy Lydia L Roboz Gail J GJ Rosti Gianantonio G Bullorsky Eduardo O EO Abruzzese Elisabetta E Hochhaus Andreas A Heim Dominik D de Souza Carmino A CA Larson Richard A RA Lipton Jeffrey H JH Khoury H Jean HJ Kim Hyeoung-Joon HJ Sillaber Christian C Hughes Timothy P TP Erben Philipp P Van Tornout Jan J Stone Richard M RM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601 21
PURPOSE Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure with imatinib. We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in ...[more]